Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRX002 and ARC-T Cells in Relapsed or Refractory AML or High-risk MDS
NCT05457010Phase 1Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- Nov 2022
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SPRX002 and ARC-T cells in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Kite Pharma. Primary endpoints: Percentage of Participants Experiencing Treatment-Emergent Adverse Events at 24 months, Percentage of Participants Experiencing Dose-Limiting Toxicities at 28 days and 1 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
SPRX002ARC-T cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05457010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05457010.